The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. The complaint for preliminary injunction will be filed under seal in the U.S. District Court for the District of Columbia. Following the Federal Trade Commission’s filing of a lawsuit to block the transaction, CSL Limited announced, on June 8, 2009, that it would not proceed with its proposed $3.1 billion acquisition of Talecris Biotherapeutics.